The process-driven system reduces total cost of ownership.
The Accelrys Process Management and Compliance Suite has been expanded with the addition of the Accelrys Laboratory Information Management System (LIMS), the company announced in a press release. This system uses a process-driven approach, which focuses on laboratory, quality-control, and manufacturing processes, in contrast to the sample-driven approach used by traditional LIMS. This process-driven approach enables organizations to achieve repeatability and consistency of procedures, automatically qualify operational changes, and maintain a lower total cost of ownership.
"Traditional systems deployed to support laboratory operations today lack the flexibility to manage the change inherent in the hand-off between departments that drive the scientific innovation cycle," said IDC Health Insights Research Director Alan Louie, PhD., in the press release. "By coming at LIMS from the process execution standpoint, companies like Accelrys are taking a more holistic approach to managing data. This approach is well suited for lab operations that are trying to drive standardization across changing environments while still maintaining process repeatability and regulatory compliance."
The Accelrys LIMS integrates with Accelrys Electronic Laboratory Notebook (ELN), Accelrys Laboratory Execution System (LES), Accelrys Electronic Batch Records (EBR), Accelrys Discoverant process management informatics, and the Accelrys Enterprise Platform (AEP) for data exchange to provide an end-to-end informatics system that makes data accessible across an organization.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.